
RNAC Stock Forecast & Price Target
RNAC Analyst Ratings
Bulls say
Cartesian Therapeutics Inc. demonstrates a robust potential for growth, as evidenced by anticipated positive outcomes from its Phase 3 trial for Descartes-08, building on the impressive results of its Phase 2 trials. The company projects substantial market penetration, aiming for approximately 30% in the U.S. and 20% across the EU5 by 2037, which reflects strong commercial viability for its innovative treatments. Additionally, the favorable tolerability and response durability of Descartes-08, along with a solid financial position, suggest a promising outlook for ongoing and future clinical developments.
Bears say
Cartesian Therapeutics Inc. reported a net loss of $0.40 per share for 4Q24 and a projected net loss of $2.75 per share for the full year 2025, indicating ongoing financial challenges. The efficacy of their lead product, Vyvgart, has shown variable clinical benefits, with the optimal therapeutic effects waning rapidly, which could hinder patient satisfaction and treatment adherence. Additionally, the company faces significant operational risks, including potential delays in clinical trials and concerns regarding the safety of their treatments, which may contribute to long-term dilution risk for shareholders.
This aggregate rating is based on analysts' research of Cartesian Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RNAC Analyst Forecast & Price Prediction
Start investing in RNAC
Order type
Buy in
Order amount
Est. shares
0 shares